Benitec Biopharma Inc. Operating Income
Benitec Biopharma Inc. (BNTC) reported Operating Income of -$51.19 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-09-14
- Benitec Biopharma Inc. operating income (loss) for the quarter ending 2026-06-30 was -$14.43M.
- Benitec Biopharma Inc. operating income (loss) for the quarter ending 2026-03-31 was -$13.58M.
- Benitec Biopharma Inc. operating income (loss) for the quarter ending 2025-12-31 was -$13.38M.
- Benitec Biopharma Inc. operating income (loss) for the quarter ending 2025-09-30 was -$9.80M.
- Benitec Biopharma Inc. operating income (loss) for fiscal 2026 was -$51.19M.
- Benitec Biopharma Inc. operating income (loss) for fiscal 2025 was -$41.77M.
- Benitec Biopharma Inc. operating income (loss) for fiscal 2024 was -$22.49M.
- Benitec Biopharma Inc. operating income (loss) for fiscal 2023 was -$19.08M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$14.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | -$28.01M derived: sum of 2 quarters · filed 2026-09-14 | -$41.39M derived: sum of 3 quarters · filed 2026-09-14 | -$51.19M 10-K · filed 2026-09-14 | |||
| 2026-03-31 | -$13.58M 10-Q · filed 2026-05-14 | -$26.96M derived: sum of 2 quarters · filed 2026-05-14 | -$36.76M 10-Q · filed 2026-05-14 | -$46.60M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-12-31 | -$13.38M 10-Q · filed 2026-02-12 | -$23.18M 10-Q · filed 2026-02-12 | -$33.01M derived: sum of 3 quarters · filed 2026-03-20 | -$48.35M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-09-30 | -$9.80M 10-Q · filed 2025-11-14 | -$19.64M derived: sum of 2 quarters · filed 2026-03-20 | -$34.97M derived: sum of 3 quarters · filed 2026-05-14 | -$45.78M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-06-30 | -$9.83M 10-K/A · filed 2026-03-20 | -$25.17M derived: sum of 2 quarters · filed 2026-05-14 | -$35.97M derived: sum of 3 quarters · filed 2026-05-14 | -$41.77M 10-K · filed 2026-09-14 | |||
| 2025-03-31 | -$15.34M 10-Q · filed 2026-05-14 | -$10.19M 10-Q · filed 2025-05-14 | -$26.14M derived: sum of 2 quarters · filed 2026-05-14 | -$31.93M 10-Q · filed 2026-05-14 | -$24.59M 10-Q · filed 2025-05-14 | -$37.48M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$10.80M 10-Q · filed 2026-02-12 | -$8.61M 10-Q · filed 2025-02-14 | -$16.60M 10-Q · filed 2026-02-12 | -$14.40M 10-Q · filed 2025-02-14 | -$22.14M derived: sum of 3 quarters · filed 2026-03-20 | -$26.29M derived: sum of 4 quarters · filed 2026-03-20 | |
| 2024-09-30 | -$5.79M 10-K/A · filed 2026-03-20 | -$11.34M derived: sum of 2 quarters · filed 2026-03-20 | -$15.48M derived: sum of 3 quarters · filed 2026-03-20 | -$22.41M derived: sum of 4 quarters · filed 2026-03-20 | |||
| 2024-06-30 | -$5.55M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | -$9.69M derived: sum of 2 quarters · filed 2026-03-20 | -$16.62M derived: sum of 3 quarters · filed 2026-03-20 | -$22.49M 10-K/A · filed 2026-03-20 | |||
| 2024-03-31 | -$4.14M 10-Q · filed 2025-05-14 | -$11.07M derived: sum of 2 quarters · filed 2025-05-14 | -$16.94M 10-Q · filed 2025-05-14 | -$21.49M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$6.93M 10-Q · filed 2025-02-14 | -$12.80M 10-Q · filed 2025-02-14 | -$17.35M derived: sum of 3 quarters · filed 2025-02-14 | -$21.69M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-09-30 | -$5.87M 10-Q · filed 2024-11-14 | -$10.42M derived: sum of 2 quarters · filed 2024-11-14 | -$14.77M derived: sum of 3 quarters · filed 2024-11-14 | -$20.38M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | -$8.89M derived: sum of 2 quarters · filed 2024-09-26 | -$14.50M derived: sum of 3 quarters · filed 2024-09-26 | -$19.08M 10-K · filed 2024-09-26 | |||
| 2023-03-31 | -$4.34M 10-Q · filed 2024-05-13 | -$9.95M derived: sum of 2 quarters · filed 2024-05-13 | -$14.53M 10-Q · filed 2024-05-13 | -$19.27M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$5.61M 10-Q · filed 2024-02-13 | -$10.19M 10-Q · filed 2024-02-13 | -$14.93M derived: sum of 3 quarters · filed 2024-02-13 | -$18.39M derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-09-30 | -$4.58M 10-Q · filed 2023-11-13 | -$9.32M derived: sum of 2 quarters · filed 2023-11-13 | -$12.78M derived: sum of 3 quarters · filed 2023-11-13 | -$17.61M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | -$4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | -$8.20M derived: sum of 2 quarters · filed 2023-09-21 | -$13.03M derived: sum of 3 quarters · filed 2023-09-21 | -$17.85M 10-K · filed 2023-09-21 | |||
| 2022-03-31 | -$3.46M 10-Q · filed 2023-05-15 | -$8.29M derived: sum of 2 quarters · filed 2023-05-15 | -$13.12M 10-Q · filed 2023-05-15 | -$16.97M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$4.83M 10-Q · filed 2023-02-13 | -$9.66M 10-Q · filed 2023-02-13 | -$13.51M derived: sum of 3 quarters · filed 2023-02-13 | -$17.30M derived: sum of 4 quarters · filed 2023-02-13 | |||
| 2021-09-30 | -$4.82M 10-Q · filed 2022-11-10 | -$8.68M derived: sum of 2 quarters · filed 2022-11-10 | -$12.47M derived: sum of 3 quarters · filed 2022-11-10 | -$15.73M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | -$7.65M derived: sum of 2 quarters · filed 2022-09-02 | -$10.91M derived: sum of 3 quarters · filed 2022-09-02 | -$13.60M 10-K · filed 2022-09-02 | |||
| 2021-03-31 | -$3.79M 10-Q · filed 2022-05-16 | -$7.05M derived: sum of 2 quarters · filed 2022-05-16 | -$9.74M 10-Q · filed 2022-05-16 | -$12.63M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$3.26M 10-Q · filed 2022-02-14 | -$5.95M 10-Q · filed 2022-02-14 | -$8.84M derived: sum of 3 quarters · filed 2022-02-14 | -$10.95M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | -$2.69M 10-Q · filed 2021-11-15 | -$5.58M derived: sum of 2 quarters · filed 2021-11-15 | -$7.69M derived: sum of 3 quarters · filed 2021-11-15 | -$9.80M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | -$5.00M derived: sum of 2 quarters · filed 2021-09-20 | -$7.11M derived: sum of 3 quarters · filed 2021-09-20 | -$8.28M 10-K · filed 2021-09-20 | |||
| 2020-03-31 | -$2.11M 10-Q · filed 2021-05-12 | -$4.22M derived: sum of 2 quarters · filed 2021-05-12 | -$5.39M 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | -$2.11M 10-Q · filed 2021-02-09 | -$3.28M 10-Q · filed 2021-02-09 | |||||
| 2019-09-30 | -$1.17M 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | $2.58M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |